Published online before print December 9, 2002, doi: 10.1161/01.CIR.0000042706.47107.7A
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:68.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
Effect of Nasal Continuous Positive Airway Pressure Treatment on Blood Pressure in Patients With Obstructive Sleep Apnea
From the Department of Respiratory Medicine, Philipps-University Marburg, Marburg, Germany, and the Department of Medicine, David Read Laboratory, University of Sydney, Australia (C.E.S.).
Correspondence to Heinrich F. Becker, Innere Med, Pneumologie, Baldingerstr D-35033 Marburg, Germany. E-mail HF.Becker{at}mailer.uni-marburg.de
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— There is increasing evidence that obstructive sleep apnea (OSA) is an independent risk factor for arterial hypertension. Because there are no controlled studies showing a substantial effect of nasal continuous positive airway pressure (nCPAP) therapy on hypertension in OSA, the impact of treatment on cardiovascular sequelae has been questioned altogether. Therefore, we studied the effect of nCPAP on arterial hypertension in patients with OSA.
Methods and Results— Sixty consecutive patients with moderate to severe OSA were randomly assigned to either effective or subtherapeutic nCPAP for 9 weeks on average. Nocturnal polysomnography and continuous noninvasive blood pressure recording for 19 hours was performed before and with treatment. Thirty two patients, 16 in each group, completed the study. Apneas and hypopneas were reduced by 
95% and 50% in the therapeutic and subtherapeutic groups, respectively. Mean arterial blood pressure decreased by 9.9±11.4 mm Hg with effective nCPAP treatment, whereas no relevant change occurred with subtherapeutic nCPAP (P=0.01). Mean, diastolic, and systolic blood pressures all decreased significantly by 10 mm Hg, both at night and during the day.
Conclusions— Effective nCPAP treatment in patients with moderate to severe OSA leads to a substantial reduction in both day and night arterial blood pressure. The fact that a 50% reduction in the apnea-hypopnea index did not result in a decrease in blood pressure emphasizes the importance of highly effective treatment. The drop in mean blood pressure by 10 mm Hg would be predicted to reduce coronary heart disease event risk by 37% and stroke risk by 56%.
Key Words: hypertension • cardiovascular diseases • sleep • blood pressure
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In recent years it has been shown that obstructive sleep apnea (OSA) is a common disorder in adults.1 OSA is characterized by repetitive apneas and hypoxia caused by upper airway collapse during sleep, despite respiratory efforts of the diaphragm. Five or more apneas per hour of sleep are generally considered abnormal, and severely affected patients have several hundred apneas each night. Most apneas and hypopneas are terminated by a transient arousal from sleep and consecutive hyperventilation. Disruption of normal sleep by frequent arousals leads to excessive daytime sleepiness, the most prominent symptom in these patients.
Nocturnal arterial blood pressure is increased in OSA patients, and there is increasing evidence that OSA is an independent risk factor for arterial hypertension during the day.2–5 Although the exact mechanisms are still unclear, a persistent increase in sympathetic tone caused by chronically occurring repetitive hypoxia and arousal are thought to be the key mechanisms for the short- and long-term blood pressure increases in OSA.6,7 It has also recently been shown that patients with OSA have an impairment of resistance-vessel endothelium-dependent vasodilation.8
Nasal continuous positive airway pressure (nCPAP) has become the standard treatment for OSA9 and has been shown in controlled studies to reduce symptoms and improve quality of life in OSA patients.10,11 Controlled studies showed either no effect12,13 or only a minor decrease in arterial blood pressure by 1.4 and 2.5 mm Hg, respectively.14,15 The effectiveness of this treatment on cardiovascular sequelae in OSA patients has been questioned altogether.16 Therefore, we performed a prospective randomized trial to evaluate the effect of nCPAP on arterial blood pressure in OSA patients.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Patients and Protocol
The study was conducted in the Sleep Unit at the University Hospital in Marburg, Germany. The Unit takes adult patients referred by general practitioners (
35%), pneumologists (35%), or other subspecialties (30%). During the study period, 283 patients fulfilled the inclusion criteria of 
5 apneas or hypopneas per hour of sleep and excessive daytime sleepiness (10 or more points out of a maximum of 24 on the Epworth sleepiness scale17; Figure 1). A maximum of 4 patients per week could be included in the study. If there was more than one patient eligible on one day, the patient with the most pronounced sleep apnea according to an ambulatory recording was asked first to participate in the study.
|
Exclusion criteria were predominantly central sleep apnea, respiratory failure, heart failure (NYHA class III or IV), myocardial infarction 3 months before the study, and relevant cardiac arrhythmia (second- and third-degree heart block or premature ventricular contractions in Lown classes IV or V). Professional drivers were also excluded. The local ethics committee approved the study, and all subjects gave written informed consent.
Sixty consecutive patients who consented to participate underwent baseline diagnostic polysomnography and continuous noninvasive blood pressure recording for 19.1±1.3 hours using the Portapres device (TNO Biomedical Instrumentation).
Patients were then randomized to receive either effective or subtherapeutic nCPAP treatment. Randomization was performed on the telephone by a person who was otherwise not involved in the study.
All study patients spent another 2 nights in the sleep laboratory to ensure adaptation to the nasal mask. Treatment was done with either the Sullivan IV (ResMed) or the Aria (Respironics) nCPAP device. In the effective treatment group, treatment pressure was increased until apneas, hypopneas, and snoring were prevented during all sleep stages and with the patient lying supine. Effective treatment pressure was 9.1±2.3 cm H2O on average (range, 6 to 12 cm H2O). In the subtherapeutic treatment group, pressure was left unchanged at the lowest possible value for the nCPAP device used (3 or 4 cm H2O, respectively).
Patients then went home on the prescribed treatment for an average of 65.2±49.6 days. They were then readmitted to the sleep laboratory, and polysomnography and continuous blood pressure measurements during daytime and sleep were repeated on either subtherapeutic or effective nCPAP treatment. Compliance was objectively measured by the built-in compliance software of the nCPAP devices.
Any antihypertensive medication the patients were taking at the beginning of the study remained unchanged throughout the entire study. Patients were considered dropouts if antihypertensive medication was accidentally changed by the patient or their general practitioner.
In 28 patients the study could not be completed because of technical problems with the blood pressure device (n=11), a change in antihypertensive treatment (n=7, 3 in the effective and 4 in the subtherapeutic nCPAP group), or the patient did not want to continue the study (n=8) or did not tolerate treatment (n=2).
Complete measurements were available in 32 patients, 16 on effective and 16 on subtherapeutic nCPAP. These data are reported here. Although arterial hypertension was neither an inclusion nor an exclusion criterion, 8 of 16 patients in the effective group and 13 of 16 patients in the subtherapeutic group turned out to be hypertensive (15 of these patients were on antihypertensive treatment and 6 had an office blood pressure of 160 and/or 90 mm Hg or more). Seven of the 15 patients on antihypertensive medication were treated with one drug (ACE inhibitor, n=4; angiotensin II receptor blocker, n=2; and calcium channel blocker, n=1). A combination of 2 antihypertensive drugs was used in 7 patients (angiotensin II receptor blocker plus diuretic, n=4; ACE inhibitor plus diuretic, n=1; ACE inhibitor plus ß-blocker, n=1; and calcium channel blocker plus diuretic, n=1), and one patient was on a combination of 4 antihypertensives (ACE inhibitor, diuretic, calcium channel blocker, and 
-blocker).
Anthropometric data and relevant diagnoses are shown in Table 1.
|
Measurements
Sleep Study Recordings
Polysomnography was performed and visually scored according to standard criteria,18,19 as detailed previously.20 The average number of apneas and hypopneas per hour of sleep (apnea-hypopnea index [AHI]) was calculated.
Blood Pressure Recording
The Portapres is a battery-operated portable instrument to measure arterial blood pressure continuously and noninvasively with 2 finger cuffs.21,22 Portapres provides a height correction to compensate for hydrostatic level effects due to movements of the measured finger with respect to the reference point at heart level. Blood pressure values measured by Portapres are in good concordance with invasively measured values21,23,24 and are highly reproducible.24,25 Because of the battery we were using, recording time was limited to 20 hours. After the elimination of artifacts, an average of 19.1±1.3 hours of blood pressure recordings were analyzed. During the diagnostic sleep study, patients spent 7.2±1 hours in bed and 7.1±1 hours on treatment. Nighttime blood pressure was calculated for this time period. Daytime blood pressure was thus recorded during the remaining 12 hours.
Patients were allowed to move freely in the hospital, but they were not able to climb stairs because the equipment was mounted on an infusion pole.
After the recording, blood pressure data were processed automatically with the software of the device, including the built-in artifact removal. No further processing of the data was done by the investigators. For each minute of the recording, the software of the device calculated mean, systolic, and diastolic blood pressure as well as heart rate.
Statistics
Mean arterial blood pressure during the entire recording period was the primary outcome variable. Secondary outcome variables were systolic and diastolic blood pressure during the entire recording period, as well as daytime and nighttime mean, systolic, and diastolic blood pressures. Tertiary outcome variables were the changes in polysomnographic parameters (AHI, sleep stages, SaO2) and sleepiness (Epworth sleepiness scale).
Statistical analysis was performed using the SPSS statistical package, version 10.0 (SPSS). Two-factor ANOVA (group versus time) with repeated measures on the factor time (baseline minus treatment) was used to test the effect of therapeutic versus subtherapeutic nCPAP. To test for differences between the 2 treatment groups at baseline and for differences in nCPAP compliance, the unpaired t test (2 sided) was used. Data are reported as mean±SD unless otherwise stated. Statistical significance was assumed at P
0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
There was a decrease in mean arterial blood pressure over the 19.1±1.3-hour recording period by 9.9±11.4 mm Hg in the therapeutic nCPAP group, but an increase by 0.6±10.8 mm Hg in the subtherapeutic nCPAP group (P=0.01, ANOVA interaction time by group). Both diastolic and systolic blood pressures also decreased significantly by 10.3±11.4 mm Hg and 9.5±15.0 mm Hg, respectively, with therapeutic nCPAP (P<0.005 and P=0.04, respectively, ANOVA interaction time by group) compared with subtherapeutic nCPAP (Figure 2). The decrease in mean blood pressure with effective nCPAP was present both during the day (-10.0±12.1 mm Hg) and night (-10.3±15.3 mm Hg). These effects of subtherapeutic and therapeutic nCPAP on blood pressure are summarized in Table 2. The time course of mean arterial blood pressure before and on treatment for both groups is shown in Figure 3. In the effective treatment group, mean arterial blood pressure decreased during the entire recording period; the most pronounced drop occurred during the night and in the morning until about noon. In the afternoon and evening, the blood pressure decrease was still present, but less pronounced, when compared with the night and the first part of the day.
|
|
|
The results of polysomnography before and on treatment are presented in Table 3. There were no significant differences in any of the variables between the 2 groups at baseline. Except for total sleep time, all parameters improved with both treatment modalities. The improvements of AHI, sleepiness, and mean SaO2 were significantly larger with therapeutic nCPAP compared with subtherapeutic nCPAP (ANOVA interaction time by group).
|
Compliance with nCPAP was high in both groups: the average use per night was 5.5±2.0 hours in the therapeutic and 5.4±2.2 hours in the subtherapeutic group (P=NS). Body weight was similar in both groups at baseline (103.1±16.5 kg and 102.6±17.8 kg in the therapeutic and subtherapeutic groups, respectively; P=NS), and it remained virtually unchanged (103.0±16.0 kg and 102.3±17.1 kg in the therapeutic and subtherapeutic groups, respectively; P=NS, ANOVA interaction time by group).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
After an average of 65 days of treatment, we found a decrease in mean arterial blood pressure by 9.9 mm Hg with effective nCPAP, whereas there was a slight increase in blood pressure with subtherapeutic nCPAP. Mean, diastolic, and systolic blood pressures decreased significantly during both the day and night by between 8.1 and 11.4 mm Hg. Although subtherapeutic nCPAP led to a significant reduction of AHI by
50%, blood pressure did not decrease. There is general agreement that nCPAP treatment leads to a reversal of apnea-associated short-term blood pressure increases during sleep26,27; however, the effect on daytime blood pressure is uncertain. Whereas 3 uncontrolled studies found a 24-hour blood pressure decrease with nCPAP,25,27,28 4 controlled studies found no significant decrease12,13 or only a minor blood pressure reduction (1.4 and 2.5 mm Hg, respectively).14,15
In contrast to these previously published controlled studies, our data show a pronounced reduction in day and night blood pressure with therapeutic nCPAP. Several factors may explain the discrepancy in the results. (1) The different results may have been caused by the fact that treatment duration was substantially longer in our study and that the use of nCPAP was high in our patients. (2) A total of 21 of our 32 patients were hypertensive, because mainly patients with moderate to severe OSA were included, whereas hypertensives were excluded in one study14 or less prevalent in the others.12,13 (3) The different methods of blood pressure measurement will influence the results. It has been shown that 24-hour ambulatory blood pressure measurement causes arousal from sleep in 64% of the recordings and leads to an increase in systolic and diastolic blood pressure by 13.7±15.9 mm Hg and 3.7±8.2 mm Hg, respectively.29 The ambulatory blood pressure measurement will therefore underestimate the changes in nighttime blood pressure caused by nCPAP. An important advantage of Portapres is that it does not cause arousal from sleep.30 Furthermore, continuous blood pressure data, as measured in our study, are in good concordance with invasively measured blood pressures, are highly reproducible,21 and therefore more accurately mirror the actual blood pressure than intermittent measurements.
There was no relevant change in body weight in either group, so this factor did not contribute to our results.
The increase in sympathetic activity caused by apnea-associated repetitive asphyxia and arousal are thought to be the key mechanisms in the pathogenesis of daytime arterial hypertension in patients with OSA. Treatment with nCPAP attenuates the increase in sympathetic activity.31 In an animal model, repetitive obstructive apneas and acoustic arousal from sleep led to a similar increase in nighttime blood pressure. However, recurrent arousal from sleep without airway obstruction did not lead to an increase in daytime blood pressure, whereas sustained hypertension developed if apneas had been produced in the animals.32 Although most polysomnographic parameters improved more markedly with effective compared with subtherapeutic nCPAP, apart from the AHI and Epworth sleepiness scale scores, only mean SaO2 was significantly higher on therapeutic than on subtherapeutic nCPAP. This finding further emphasizes the role of hypoxia in the evolution of daytime arterial hypertension and the importance of preventing hypoxia to achieve optimal treatment of arterial hypertension in OSA patients.
In our study there was a substantial number of drop outs, mainly because of technical problems and changes in antihypertensive medication. Portapres is a complex device and is therefore more prone to technical problems than ambulatory blood pressure measurement. Because technical defects and accidental changes in medication occurred in both groups in a similar number of patients, this should not have influenced our results.
The reduced number of patients that could be included in the final analysis has reduced power from the statistical tests performed; however, because of the large effect of therapeutic nCPAP on blood pressure, differences in primary and secondary outcome variables were significant.
We used a single-blind study design because a method for applying therapeutic and subtherapeutic nCPAP in a double-blind fashion was not available. The knowledge of the allocation to one or the other treatment group might have influenced the analysis of our data. Polysomnography was therefore scored by a technician who was not informed about the study, and blood pressure analysis, including artifact recognition and elimination, was done exclusively by the software of the Portapres device. The risk of a bias due to the single-blind design was thus minimized.
Unexpectedly, nCPAP at a pressure of 3 or 4 cm H2O reduced mean AHI by 50%, improved sleep structure, and reduced desaturation. NCPAP at the pressure applied is therefore not a placebo but a suboptimal form of treatment, because even the low treatment pressure used here may be sufficient to at least partly reverse upper airway obstruction in many patients. However, the reduction in AHI in the control group would have acted against our hypothesis that nCPAP lowers blood pressure. Despite the reduction in AHI in the subtherapeutic treatment group by 50%, there was no reduction in blood pressure in this group. The unexpected result that suboptimal nCPAP has a substantial effect on AHI but no effect on blood pressure emphasizes the importance of optimal treatment to reduce cardiovascular sequelae.
This is the first prospective, randomized study to demonstrate a substantial reduction in arterial blood pressure during both the day and night with 9 weeks of therapeutic nCPAP treatment compared with subtherapeutic nCPAP. Although AHI was reduced by 50% with subtherapeutic nCPAP, there was no effect on blood pressure, emphasizing the importance of optimal treatment. In our study, the drop in mean blood pressure was close to 10 mm Hg. This would be predicted to reduce coronary heart disease event risk by 37% and stroke risk by 56%.33
|
Acknowledgments |
|---|
Supported in part by grants from ResMed Germany (Mönchengladbach, Germany) and Heinen & Löwenstein (Bad Ems, Germany). We thank Wilma Althaus for technical assistance with the scoring of the sleep studies and Werner Cassel for his assistance with the statistical analysis. We thank Dr John Stradling for his valuable comments and discussion of the manuscript.
|
Footnotes |
|---|
Dr Sullivan is a minor shareholder of ResMed Inc.
Received May 17, 2002; revision received September 19, 2002; accepted September 26, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993; 328: 1230–1235.
2. Grote L, Ploch T, Heitmann J, et al. Sleep-related breathing disorder is an independent risk factor for systemic hypertension. Am J Respir Crit Care Med. 1999; 160: 1875–1882.
3. Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000; 342: 1378–1384.
4. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study: Sleep Heart Health Study. JAMA. 2000; 283: 1829–1836.
5. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ. 2000; 320: 479–482.
6. Carlson JT, Hedner J, Elam M, et al. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest. 1993; 103: 1763–1768.
7. Narkiewicz K, van de Borne PJ, Cooley RL, et al. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation. 1998; 98: 772–776.
8. Kato M, Roberts-Thomson P, Phillips BG, et al. Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation. 2000; 102: 2607–2610.
9. Sullivan CE, Issa FG, Berthon-Jones M, et al. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet. 1981; 1: 862–865.[Medline] [Order article via Infotrieve]
10. Engleman HM, Martin SE, Deary IJ, et al. Effect of continuous positive airway pressure treatment on daytime function in sleep apnoea/hypopnoea syndrome. Lancet. 1994; 343: 572–575.[CrossRef][Medline] [Order article via Infotrieve]
11. Jenkinson C, Davies RJ, Mullins R, et al. Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet. 1999; 353: 2100–2105.[CrossRef][Medline] [Order article via Infotrieve]
12. Dimsdale JE, Loredo JS, Profant J. Effect of continuous positive airway pressure on blood pressure: a placebo trial. Hypertension. 2000; 35: 144–147.
13. Engleman HM, Gough K, Martin SE, et al. Ambulatory blood pressure on and off continuous positive airway pressure therapy for the sleep apnea/hypopnea syndrome: effects in "non-dippers". Sleep. 1996; 19: 378–381.[Medline] [Order article via Infotrieve]
14. Faccenda JF, Mackay TW, Boon NA, et al. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med. 2001; 163: 344–348.
15. Pepperell JC, Ramdassingh-Dow S, et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet. 2002; 359: 204–210.[CrossRef][Medline] [Order article via Infotrieve]
16. Wright J, Johns R, Watt I, et al. Health effects of obstructive sleep apnoea and the effectiveness of continuous positive airways pressure: a systematic review of the research evidence. BMJ. 1997; 314: 851–860.
17. Johns MW. Daytime sleepiness, snoring, and obstructive sleep apnea: the Epworth sleepiness scale. Chest. 1993; 103: 30–36.
18. Rechtschaffen A, Kales A. A Manual of Standardized Terminology: Techniques and Scoring System for Sleep Stages of Human Subjects. Los Angeles: UCLA Brain Information Service/Brain Research Institute; 1968.
19. American Thoracic Society. Indications and standards for cardiopulmonary sleep studies. Am Rev Respir Dis. 1989; 139: 559–568.[Medline] [Order article via Infotrieve]
20. Becker HF, Piper AJ, Flynn WE, et al. Breathing during sleep in patients with nocturnal desaturation. Am J Respir Crit Care Med. 1999; 159: 112–118.
21. Imholz BP, Langewouters GJ, van Montfrans GA, et al. Feasibility of ambulatory, continuous 24-hour finger arterial pressure recording. Hypertension. 1993; 21: 65–73.
22. Bos WJ, van Goudoever J, van Montfrans GA, et al. Reconstruction of brachial artery pressure from noninvasive finger pressure measurements. Circulation. 1996; 94: 1870–1875.
23. Hirschl MM, Binder M, Herkner H, et al. Accuracy and reliability of noninvasive continuous finger blood pressure measurement in critically ill patients. Crit Care Med. 1996; 24: 1684–1689.[CrossRef][Medline] [Order article via Infotrieve]
24. Voogel AJ, van Montfrans GA. Reproducibility of twenty-four-hour finger arterial blood pressure, variability and systemic hemodynamics. J Hypertens. 1997; 15: 1761–1765.[CrossRef][Medline] [Order article via Infotrieve]
25. Voogel AJ, van Steenwijk RP, Karemaker JM at al. Effects of treatment of obstructive sleep apnea on circadian hemodynamics. J Auton Nerv Syst. 1999; 77: 177–183.[CrossRef][Medline] [Order article via Infotrieve]
26. Mayer J, Becker H, Brandenburg U, et al. Blood pressure and sleep apnea: results of long-term nasal continuous positive airway pressure therapy. Cardiology. 1991; 79: 84–92.[Medline] [Order article via Infotrieve]
27. Jennum P, Wildschiodtz G, Christensen NJ, et al. Blood pressure, catecholamines, and pancreatic polypeptide in obstructive sleep apnea with and without nasal continuous positive airway pressure (nCPAP) treatment. Am J Hypertens. 1989; 2: 847–852.[Medline] [Order article via Infotrieve]
28. Wilcox I, Grunstein RR, Hedner JA, et al. Effect of nasal continuous positive airway pressure during sleep on 24-hour blood pressure in obstructive sleep apnea. Sleep. 1993; 16: 539–544.[Medline] [Order article via Infotrieve]
29. Heude E, Bourgin P, Feigel P, et al. Ambulatory monitoring of blood pressure disturbs sleep and raises systolic pressure at night in patients suspected of suffering from sleep-disordered breathing. Clin Sci (Colch). 1996; 91: 45–50.[Medline] [Order article via Infotrieve]
30. Jerrentrup A, Becker HF, Heitmann J, et al. Does continuous non-invasive blood pressure recording affect sleep quality in patients with nCPAP-therapy? Eur Respir J. 1999; 14: 85s. Abstract.
31. Somers VK, Dyken ME, Clary MP, et al. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995; 96: 1897–1904.[Medline] [Order article via Infotrieve]
32. Brooks D, Horner RL, Kozar LF, et al. Obstructive sleep apnea as a cause of systemic hypertension. Evidence from a canine model. J Clin Invest. 1997; 99: 106–109.[Medline] [Order article via Infotrieve]
33. Macmahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335: 765–774.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  A. Khan, K. Ramar, S. Maddirala, O. Friedman, J. F. Pallanch, and E. J. Olson Uvulopalatopharyngoplasty in the Management of Obstructive Sleep Apnea: The Mayo Clinic Experience Mayo Clin. Proc., September 1, 2009; 84(9): 795 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Ryan, C T Taylor, and W T McNicholas Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Thorax, July 1, 2009; 64(7): 631 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ishida, M. Kato, Y. Kato, K. Yanagihara, Y. Kinugasa, K. Kotani, O. Igawa, I. Hisatome, C. Shigemasa, and V. K. Somers Appropriate Use of Nasal Continuous Positive Airway Pressure Decreases Elevated C-Reactive Protein in Patients With Obstructive Sleep Apnea Chest, July 1, 2009; 136(1): 125 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Akar Bayram, B. Ciftci, T. Durmaz, T. Keles, E. Yeter, M. Akcay, and E. Bozkurt Effects of continuous positive airway pressure therapy on left ventricular function assessed by tissue Doppler imaging in patients with obstructive sleep apnoea syndrome Eur J Echocardiogr, May 1, 2009; 10(3): 376 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Yaggi Sleep and the Cardiovascular System ACCP Sleep Med Brd Rev, January 1, 2009; 4(0): 123 - 132. [Full Text] [PDF]
|
|
|
|
|
|
A. Malhotra Obstructive Sleep Apnea and Central Sleep Apnea: Epidemiology, Pathophysiology, and Risk Factors ACCP Sleep Med Brd Rev, January 1, 2009; 4(0): 193 - 200. [Full Text] [PDF]
|
|
|
|
 |
|
 U. Kuhlmann, F. G. Bormann, and H. F. Becker Obstructive sleep apnoea: clinical signs, diagnosis and treatment Nephrol. Dial. Transplant., January 1, 2009; 24(1): 8 - 14. [Full Text] [PDF]
|
|
|
|
|
|
R. N. Khayat, W. T. Abraham, B. Patt, M. Roy, K. Hua, and D. Jarjoura Cardiac Effects of Continuous and Bilevel Positive Airway Pressure for Patients With Heart Failure and Obstructive Sleep Apnea: A Pilot Study Chest, December 1, 2008; 134(6): 1162 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lorenzi-Filho and L. F. Drager Is the Cardiovascular System the Primary Target of Obstructive Sleep Apnea? Am. J. Respir. Crit. Care Med., November 1, 2008; 178(9): 892 - 893. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Levy, J-L. Pepin, C. Arnaud, R. Tamisier, J-C. Borel, M. Dematteis, D. Godin-Ribuot, and C. Ribuot Intermittent hypoxia and sleep-disordered breathing: current concepts and perspectives Eur. Respir. J., October 1, 2008; 32(4): 1082 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G V Robinson, B A Langford, D M Smith, and J R Stradling Predictors of blood pressure fall with continuous positive airway pressure (CPAP) treatment of obstructive sleep apnoea (OSA) Thorax, October 1, 2008; 63(10): 855 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. K. Somers, D. P. White, R. Amin, W. T. Abraham, F. Costa, A. Culebras, S. Daniels, J. S. Floras, C. E. Hunt, L. J. Olson, et al. Sleep Apnea and Cardiovascular Disease: An American Heart Association/American College of Cardiology Foundation Scientific Statement From the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing In Collaboration With the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health) Circulation, September 2, 2008; 118(10): 1080 - 1111. [Full Text] [PDF]
|
|
|
|
|
|
F. Valham, T. Mooe, T. Rabben, H. Stenlund, U. Wiklund, and K. A. Franklin Increased Risk of Stroke in Patients With Coronary Artery Disease and Sleep Apnea: A 10-Year Follow-Up Circulation, August 26, 2008; 118(9): 955 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. K. Somers, D. P. White, R. Amin, W. T. Abraham, F. Costa, A. Culebras, S. Daniels, J. S. Floras, C. E. Hunt, L. J. Olson, et al. Sleep Apnea and Cardiovascular Disease: An American Heart Association/American College of Cardiology Foundation Scientific Statement From the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing In Collaboration With the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health) J. Am. Coll. Cardiol., August 19, 2008; 52(8): 686 - 717. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Carneiro, S. M. Togeiro, L. F. Hayashi, F. F. Ribeiro-Filho, A. B. Ribeiro, S. Tufik, and M. T. Zanella Effect of continuous positive airway pressure therapy on hypothalamic-pituitary-adrenal axis function and 24-h blood pressure profile in obese men with obstructive sleep apnea syndrome Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E380 - E384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Calhoun, D. Jones, S. Textor, D. C. Goff, T. P. Murphy, R. D. Toto, A. White, W. C. Cushman, W. White, D. Sica, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Circulation, June 24, 2008; 117(25): e510 - e526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Calhoun, D. Jones, S. Textor, D. C. Goff, T. P. Murphy, R. D. Toto, A. White, W. C. Cushman, W. White, D. Sica, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension, June 1, 2008; 51(6): 1403 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Marrone, A. Salvaggio, S. Romano, and G. Insalaco Automatic Titration and Calculation by Predictive Equations for the Determination of Therapeutic Continuous Positive Airway Pressure for Obstructive Sleep Apnea Chest, March 1, 2008; 133(3): 670 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kapa, F. H. Sert Kuniyoshi, and V. K. Somers Sleep Apnea and Hypertension: Interactions and Implications for Management Hypertension, March 1, 2008; 51(3): 605 - 608. [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. McNicholas Diagnosis of Obstructive Sleep Apnea in Adults Proceedings of the ATS, February 15, 2008; 5(2): 154 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Sanders, J. M. Montserrat, R. Farre, and R. J. Givelber Positive Pressure Therapy: A Perspective on Evidence-based Outcomes and Methods of Application Proceedings of the ATS, February 15, 2008; 5(2): 161 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Golbin, V. K. Somers, and S. M. Caples Obstructive Sleep Apnea, Cardiovascular Disease, and Pulmonary Hypertension Proceedings of the ATS, February 15, 2008; 5(2): 200 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Amit Benjamin and K E Lewis Sleep-disordered breathing and cardiovascular disease Postgrad. Med. J., January 1, 2008; 84(987): 15 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Han, V. V. McLaughlin, G. J. Criner, and F. J. Martinez Pulmonary Diseases and the Heart Circulation, December 18, 2007; 116(25): 2992 - 3005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Buchner, B. M. Sanner, J. Borgel, and L. C. Rump Continuous Positive Airway Pressure Treatment of Mild to Moderate Obstructive Sleep Apnea Reduces Cardiovascular Risk Am. J. Respir. Crit. Care Med., December 15, 2007; 176(12): 1274 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Goncalves, D. Martinez, M. Gus, E. O. de Abreu-Silva, C. Bertoluci, I. Dutra, T. Branchi, L. B. Moreira, S. C. Fuchs, A. C. T. de Oliveira, et al. Obstructive Sleep Apnea and Resistant Hypertension: A Case-Control Study Chest, December 1, 2007; 132(6): 1858 - 1862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Buyse, J. Hedner, and the participants of working group 2 Sleep apnoea, hypertension and vascular disease: where are we now? Eur. Respir. Rev., December 1, 2007; 16(106): 169 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Campos-Rodriguez, J. Perez-Ronchel, A. Grilo-Reina, J. Lima-Alvarez, M. A. Benitez, and C. Almeida-Gonzalez Long-term Effect of Continuous Positive Airway Pressure on BP in Patients With Hypertension and Sleep Apnea Chest, December 1, 2007; 132(6): 1847 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Beecroft, J. Zaltzman, R. Prasad, G. Meliton, and P. J. Hanly Impact of kidney transplantation on sleep apnoea in patients with end-stage renal disease Nephrol. Dial. Transplant., October 1, 2007; 22(10): 3028 - 3033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Punjabi, B. A. Beamer, A. Jain, M. E. Spencer, and N. Fedarko Elevated Levels of Neopterin in Sleep-Disordered Breathing Chest, October 1, 2007; 132(4): 1124 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. McNicholas Cardiovascular outcomes of CPAP therapy in obstructive sleep apnea syndrome Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1666 - R1670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Parati, C. Lombardi, and K. Narkiewicz Sleep apnea: epidemiology, pathophysiology, and relation to cardiovascular risk Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1671 - R1683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Kakkar and R. B. Berry Positive Airway Pressure Treatment for Obstructive Sleep Apnea Chest, September 1, 2007; 132(3): 1057 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Bazzano, Z. Khan, K. Reynolds, and J. He Effect of Nocturnal Nasal Continuous Positive Airway Pressure on Blood Pressure in Obstructive Sleep Apnea Hypertension, August 1, 2007; 50(2): 417 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Montserrat, F. Garcia-Rio, and F. Barbe Diagnostic and Therapeutic Approach to Nonsleepy Apnea Am. J. Respir. Crit. Care Med., July 1, 2007; 176(1): 6 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Martinez-Garcia, R. Gomez-Aldaravi, J-J. Soler-Cataluna, T. G. Martinez, B. Bernacer-Alpera, and P. Roman-Sanchez Positive effect of CPAP treatment on the control of difficult-to-treat hypertension Eur. Respir. J., May 1, 2007; 29(5): 951 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Patruno, S. Aiolfi, G. Costantino, R. Murgia, C. Selmi, A. Malliani, and N. Montano Fixed and Autoadjusting Continuous Positive Airway Pressure Treatments Are Not Similar in Reducing Cardiovascular Risk Factors in Patients With Obstructive Sleep Apnea Chest, May 1, 2007; 131(5): 1393 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Imadojemu, Z. Mawji, A. Kunselman, K. S. Gray, C. S. Hogeman, and U. A. Leuenberger Sympathetic Chemoreflex Responses in Obstructive Sleep Apnea and Effects of Continuous Positive Airway Pressure Therapy Chest, May 1, 2007; 131(5): 1406 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Basner Continuous Positive Airway Pressure for Obstructive Sleep Apnea N. Engl. J. Med., April 26, 2007; 356(17): 1751 - 1758. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Haentjens, A. Van Meerhaeghe, A. Moscariello, S. De Weerdt, K. Poppe, A. Dupont, and B. Velkeniers The Impact of Continuous Positive Airway Pressure on Blood Pressure in Patients With Obstructive Sleep Apnea Syndrome: Evidence From a Meta-analysis of Placebo-Controlled Randomized Trials Arch Intern Med, April 23, 2007; 167(8): 757 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Coruzzi, M. Gualerzi, E. Bernkopf, L. Brambilla, V. Brambilla, V. Broia, C. Lombardi, and G. Parati Autonomic Cardiac Modulation in Obstructive Sleep Apnea: Effect of an Oral Jaw-Positioning Appliance. Chest, November 1, 2006; 130(5): 1362 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Bradshaw, G. A. Ruff, and D. P. Murphy An oral hypnotic medication does not improve continuous positive airway pressure compliance in men with obstructive sleep apnea. Chest, November 1, 2006; 130(5): 1369 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sumi, K. Chin, K. Takahashi, T. Nakamura, H. Matsumoto, A. Niimi, and M. Mishima Effect of nCPAP therapy on heart rate in patients with obstructive sleep apnoea-hypopnoea QJM, August 1, 2006; 99(8): 545 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Circulation, June 20, 2006; 113(24): e873 - e923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Campos-Rodriguez, A. Grilo-Reina, J. Perez-Ronchel, M. Merino-Sanchez, M. A. Gonzalez-Benitez, M. Beltran-Robles, and C. Almeida-Gonzalez Effect of Continuous Positive Airway Pressure on Ambulatory BP in Patients With Sleep Apnea and Hypertension: A Placebo-Controlled Trial Chest, June 1, 2006; 129(6): 1459 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. V. Robinson, D. M. Smith, B. A. Langford, R. J. O. Davies, and J. R. Stradling Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients Eur. Respir. J., June 1, 2006; 27(6): 1229 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N T Ayas, G B J Mancini, and J Fleetham Does CPAP delay the development of cardiovascular disease in patients with obstructive sleep apnoea hypopnoea? Thorax, June 1, 2006; 61(6): 459 - 460. [Full Text] [PDF]
|
|
|
|
|
|
J L Lattimore, I Wilcox, M Skilton, M Langenfeld, and D S Celermajer Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation Thorax, June 1, 2006; 61(6): 491 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke, June 1, 2006; 37(6): 1583 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ferreira, J. Winck, P. Bettencourt, and F. Rocha-Goncalves Heart failure and sleep apnoea: To sleep perchance to dream Eur J Heart Fail, May 1, 2006; 8(3): 227 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Norman, J. S. Loredo, R. A. Nelesen, S. Ancoli-Israel, P. J. Mills, M. G. Ziegler, and J. E. Dimsdale Effects of Continuous Positive Airway Pressure Versus Supplemental Oxygen on 24-Hour Ambulatory Blood Pressure Hypertension, May 1, 2006; 47(5): 840 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Sert Kuniyoshi and V. K. Somers Sleep Apnea in Hypertension: When, How, and Why Should We Treat? Hypertension, May 1, 2006; 47(5): 818 - 819. [Full Text] [PDF]
|
|
|
|
|
|
J. Hedner, K. Bengtsson-Bostrom, Y. Peker, L. Grote, L. Rastam, and U. Lindblad Hypertension prevalence in obstructive sleep apnoea and sex: a population-based case-control study. Eur. Respir. J., March 1, 2006; 27(3): 564 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Blankfield Can Natriuretic Peptide Levels Predict the Cardiovascular Complications of COX-2 Inhibitors and Nonsteroidal Anti-inflammatory Drugs? J Am Board Fam Med, March 1, 2006; 19(2): 178 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Mulgrew and J A Fleetham How best to determine optimal nasal CPAP in patients with OSAH? Thorax, March 1, 2006; 61(3): 186 - 187. [Full Text] [PDF]
|
|
|
|
|
|
D. Yinon, L. Lowenstein, S. Suraya, R. Beloosesky, O. Zmora, A. Malhotra, and G. Pillar Pre-eclampsia is associated with sleep-disordered breathing and endothelial dysfunction Eur. Respir. J., February 1, 2006; 27(2): 328 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Mills, B. P. Kennedy, J. S. Loredo, J. E. Dimsdale, and M. G. Ziegler Effects of nasal continuous positive airway pressure and oxygen supplementation on norepinephrine kinetics and cardiovascular responses in obstructive sleep apnea J Appl Physiol, January 1, 2006; 100(1): 343 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. White Sleep apnea. Proceedings of the ATS, January 1, 2006; 3(1): 124 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Pack Advances in Sleep-disordered Breathing Am. J. Respir. Crit. Care Med., January 1, 2006; 173(1): 7 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Arzt, T. Young, L. Finn, J. B. Skatrud, and T. D. Bradley Association of Sleep-disordered Breathing and the Occurrence of Stroke Am. J. Respir. Crit. Care Med., December 1, 2005; 172(11): 1447 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Yaggi, J. Concato, W. N. Kernan, J. H. Lichtman, L. M. Brass, and V. Mohsenin Obstructive Sleep Apnea as a Risk Factor for Stroke and Death. N. Engl. J. Med., November 10, 2005; 353(19): 2034 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Caples, A. S. Gami, and V. K. Somers Obstructive Sleep Apnea Focus, October 1, 2005; 3(4): 557 - 567. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Martinez-Garcia, R. Galiano-Blancart, P. Roman-Sanchez, J.-J. Soler-Cataluna, L. Cabero-Salt, and E. Salcedo-Maiques Continuous Positive Airway Pressure Treatment in Sleep Apnea Prevents New Vascular Events After Ischemic Stroke Chest, October 1, 2005; 128(4): 2123 - 2129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Huang, D. P. White, and A. Malhotra The Impact of Anatomic Manipulations on Pharyngeal Collapse: Results From a Computational Model of the Normal Human Upper Airway Chest, September 1, 2005; 128(3): 1324 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Campos-Rodriguez, N. Pena-Grinan, N. Reyes-Nunez, I. De la Cruz-Moron, J. Perez-Ronchel, F. De la Vega-Gallardo, and A. Fernandez-Palacin Mortality in Obstructive Sleep Apnea-Hypopnea Patients Treated With Positive Airway Pressure Chest, August 1, 2005; 128(2): 624 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Arias, F. Garcia-Rio, A. Alonso-Fernandez, O. Mediano, I. Martinez, and J. Villamor Obstructive Sleep Apnea Syndrome Affects Left Ventricular Diastolic Function: Effects of Nasal Continuous Positive Airway Pressure in Men Circulation, July 19, 2005; 112(3): 375 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Floras and T. D. Bradley Atrial Overdrive Pacing for Sleep Apnea: A Door Now Closed? Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 1 - 3. [Full Text] [PDF]
|
|
|
|
|
|
K. Usui, T. D. Bradley, J. Spaak, C. M. Ryan, T. Kubo, Y. Kaneko, and J. S. Floras Inhibition of Awake Sympathetic Nerve Activity of Heart Failure Patients With Obstructive Sleep Apnea by Nocturnal Continuous Positive Airway Pressure J. Am. Coll. Cardiol., June 21, 2005; 45(12): 2008 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Doherty, J. L. Kiely, V. Swan, and W. T. McNicholas Long-term Effects of Nasal Continuous Positive Airway Pressure Therapy on Cardiovascular Outcomes in Sleep Apnea Syndrome Chest, June 1, 2005; 127(6): 2076 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schulz The vascular micromilieu in obstructive sleep apnoea Eur. Respir. J., May 1, 2005; 25(5): 780 - 782. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Caples, A. S. Gami, and V. K. Somers Obstructive Sleep Apnea Ann Intern Med, February 1, 2005; 142(3): 187 - 197. [Full Text] [PDF]
|
|
|
|
|
|
S. H. Feinsilver A Sleeping Giant: Sleep-Disordered Breathing in the Coronary Care Unit Chest, January 1, 2005; 127(1): 4 - 5. [Full Text] [PDF]
|
|
|
|
|
|
L. Lin, L. Finn, J. Zhang, T. Young, and E. Mignot Angiotensin-converting Enzyme, Sleep-disordered Breathing, and Hypertension Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1349 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Stradling Reducing the Cost of Treating Obstructive Sleep Apnea: Good News for Patients Am. J. Respir. Crit. Care Med., December 1, 2004; 170(11): 1143 - 1144. [Full Text] [PDF]
|
|
|
|
|
|
G V Robinson, J R Stradling, and R J O Davies Sleep {middle dot} 6: Obstructive sleep apnoea/hypopnoea syndrome and hypertension Thorax, December 1, 2004; 59(12): 1089 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Barnes, R. D. McEvoy, S. Banks, N. Tarquinio, C. G. Murray, N. Vowles, and R. J. Pierce Efficacy of Positive Airway Pressure and Oral Appliance in Mild to Moderate Obstructive Sleep Apnea Am. J. Respir. Crit. Care Med., September 15, 2004; 170(6): 656 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Stammnitz, A. Jerrentrup, T. Penzel, J.H. Peter, C. Vogelmeier, and H.F. Becker Automatic CPAP titration with different self-setting devices in patients with obstructive sleep apnoea Eur. Respir. J., August 1, 2004; 24(2): 273 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Parish and V. K. Somers Obstructive Sleep Apnea and Cardiovascular Disease Mayo Clin. Proc., August 1, 2004; 79(8): 1036 - 1046. [Abstract] [PDF]
|
|
|
|
|
|
F. Gagnadoux, X.L. Nguyen, D. Rakotonanahary, S. Vidal, and B. Fleury Wrist-actigraphic estimation of sleep time under nCPAP treatment in sleep apnoea patients Eur. Respir. J., June 1, 2004; 23(6): 891 - 895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Milleron, R. Pilliere, A. Foucher, F. de Roquefeuil, P. Aegerter, G. Jondeau, B. G Raffestin, and O. Dubourg Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study Eur. Heart J., May 1, 2004; 25(9): 728 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.M. Sanner, P. Kollhosser, N. Buechner, W. Zidek, and M. Tepel Influence of treatment on leptin levels in patients with obstructive sleep apnoea Eur. Respir. J., April 1, 2004; 23(4): 601 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Fietze, D. Romberg, M. Glos, S. Endres, H. Theres, C. Witt, and V. K. Somers Effects of positive-pressure ventilation on the spontaneous baroreflex in healthy subjects J Appl Physiol, March 1, 2004; 96(3): 1155 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Heitmann, K. Ehlenz, T. Penzel, H.F. Becker, L. Grote, K.H. Voigt, J. Hermann Peter, and C. Vogelmeier Sympathetic activity is reduced by nCPAP in hypertensive obstructive sleep apnoea patients Eur. Respir. J., February 1, 2004; 23(2): 255 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Mansfield, N. C. Gollogly, D. M. Kaye, M. Richardson, P. Bergin, and M. T. Naughton Controlled Trial of Continuous Positive Airway Pressure in Obstructive Sleep Apnea and Heart Failure Am. J. Respir. Crit. Care Med., February 1, 2004; 169(3): 361 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lavie Pro: Sleep Apnea Causes Cardiovascular Disease Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 147 - 148. [Full Text] [PDF]
|
|
|
|
|
|
J. Stradling Con: Sleep Apnea Does Not Cause Cardiovascular Disease Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 148 - 149. [Full Text] [PDF]
|
|
|
|
|
|
N. J. Douglas and J. Black Modafinil and Sleepiness Am. J. Respir. Crit. Care Med., December 15, 2003; 168(12): 1538 - 1539. [Full Text] [PDF]
|
|
|
|
|
|
R. Wolk, A. S.M. Shamsuzzaman, and V. K. Somers Obesity, Sleep Apnea, and Hypertension Hypertension, December 1, 2003; 42(6): 1067 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Chobanian, G. L. Bakris, H. R. Black, W. C. Cushman, L. A. Green, J. L. Izzo Jr, D. W. Jones, B. J. Materson, S. Oparil, J. T. Wright Jr, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension, December 1, 2003; 42(6): 1206 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. M. Shamsuzzaman, B. J. Gersh, and V. K. Somers Obstructive Sleep Apnea: Implications for Cardiac and Vascular Disease JAMA, October 8, 2003; 290(14): 1906 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wolk, T. Kara, and V. K. Somers Sleep-Disordered Breathing and Cardiovascular Disease Circulation, July 8, 2003; 108(1): 9 - 12. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||